Whoops, your site does not have a menu!

Project ALS and Amylyx Enter Collaboration to Test AMX0035

Home
news
Project ALS and Amylyx Enter Collaboration to Test AMX0035

Project ALS and Amylyx Enter Collaboration to Test AMX0035

Amylyx closes a $ 5 million Series A Investment

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Recent Posts

Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO
Search for cure against the lethal disease ALS boosted by new investor
Orphazyme closes a €14 million Series B Extension
Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
Project ALS and Amylyx Enter Collaboration to Test AMX0035